Drug Profile
Rasdegafusp alfa - Celldex Therapeutics Inc
Alternative Names: CDX-1401; DEC-205/NY-ESO-1 vaccine - Celldex; Rasdegafusp alfaLatest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator Ludwig Institute for Cancer Research
- Developer Celldex Therapeutics Inc; National Cancer Institute (USA); Roswell Park Cancer Institute
- Class Cancer vaccines; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; DEC-205 receptor agonists; Dendritic cell stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Fallopian tube cancer; Gynaecological cancer; Malignant melanoma; Myelodysplastic syndromes; Ovarian cancer; Peritoneal cancer; Solid tumours
Most Recent Events
- 09 Dec 2023 The efficacy data from a phase I trial in Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 25 Aug 2021 Roswell Park Cancer Institute and Celldex Therapeutics completes a phase I trial in Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, Myelodysplastic syndromes (Combination therapy) in USA (NCT03358719)
- 18 May 2018 National Cancer Institute completes a phase II trial in Malignant melanoma in USA (NCT02129075)